Study: XARELTO(R)(rivaroxaban)offers net clinical benefit for the treatment of deep-vein thrombosis
The EINSTEIN-DVT study reinforces that XARELTO is a simple and convenient treatment option for clinicians and patients alike
Bayer HealthCare Pharmaceuticals today announced that XARELTO(R) (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis (DVT). DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood. It is estimated that DVT affects 45,000 Canadians per year(1).
Read Full Article...
Welcome to CFP’s Comment Section!
The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.
Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.
Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.
We ask only that commenters keep it civil, keep it clean.
Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.
READ OUR Commenting Policy